Mobilization of hematopoetic stem cells using plerixafor - experience of the Czech Republic transplantation centers
Abstract
Plerixafor is a novel kind of drug which administration leads to a hematopoietic stem and progenitor cells (HSC) mobilization independently of chemotherapy or G-CSF. Plerixafor is a small molecule bicyclam derivate and inhibits reversibly the SDF-1/CXCR4 interaction, which belongs to the most important mechanisms binding HSC to the bone marrow microenvironment.
Inhibition of SDF-1/CXCR4 interaction results in a fast mobilization of HSC into a peripheral blood. Plerixafor is a very valuable substance especially for patients who are not able to mobilize sufficient numbers of HSC after G-CSF +- chemotherapy and, therefore, who are not the candidates for autologous peripheral blood stem cells (PBSC) transplantation because they are not able to collect adequate transplants.
The aim of this study is to evaluate results reached with plerixafor in transplant centres in Czech Republic.